Wednesday, April 2, 2025
15 C
London
HomeFinTechInteRNA Technologies: Extends Series B Financing Round Totaling €18.5M

InteRNA Technologies: Extends Series B Financing Round Totaling €18.5M

Date:

Visa Proposes $100 Million to Apple: A Move to Ditch Mastercard

Exploring the Implications of Visa's Bold Financial Offer to...

PayPal Launches Innovative Advertising Platform in the UK

Revolutionizing Digital Marketing with Targeted Solutions for BusinessesHighlights: PayPal...

Ayan Capital Secures $25 Million in Shariah-Compliant Debt Funding

Unlocking Opportunities in Islamic Finance: Ayan Capital's Strategic MoveHighlights:...
  • InteRNA Technologies, The Netherlands-based company that designs new therapies tackling cancer, closed an extended Series B financing round amounting to €18.5M in total
  • This Series B round led by AurorA Science, an Italian biotech investment company, along with existing investor Waterman Ventures
  • Current shareholders Aglaia Oncology Funds and OostNL also contributed to the financing round
  • The funding will enable the clinical evaluation of the company’s microRNA lead candidate, INT-1B3, in patients with advanced solid tumors
  • Furthermore, the proceeds will used to develop and advance additional proprietary preclinical drug candidates adressing a variety of cancer indications thereby expanding InteRNA’s pipeline
  • The company’s microRNA lead candidate, INT-1B3, has a mechanism of action that addresses multiple hallmarks of cancer simultaneously

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories